文献速递中毒与环境急症消化、代谢与肾脏急症重症综合管理与镇静镇痛

氟美吡唑作为对乙酰氨基酚中毒的辅助治疗:2015-2020年毒理学研究者联盟(ToxIC)数据库报告病例

Fomepizole as an adjunctive therapy for acetaminophen poisoning: cases reported to the toxicology investigators consortium (ToxIC) database 2015-2020.
PubMed 文献 · Clin Toxicol (Phila) · 2022-05-05
一句话结论严重对乙酰氨基酚中毒危重患者中,氟美吡唑作为辅助治疗的使用频率增加,但当前使用模式尚不明确。

本文为ToxIC数据库2015年1月至2020年7月的二次分析,纳入对乙酰氨基酚(APAP)摄入并接受氟美吡唑治疗的病例,排除APAP非主要毒物、未用N-乙酰半胱氨酸(NAC)或氟美吡唑明确用于其他适应症者,共25例。72%发生肝毒性(AST或ALT > 1000 IU/L),40%发生凝血障碍(PT > 15s),72%代谢性酸中毒(pH <7.20),48%插管,36%使用血管加压药,24%接受连续肾脏替代治疗,总死亡率24%。作者认为氟美吡唑在少数危重急性APAP中毒患者中的使用频率正在增加。

要点

  • 25例APAP中毒接受氟美吡唑治疗者中,72%(18/25)发生肝毒性(AST或ALT > 1000 IU/L)。
  • 该人群病情危重:72%(18/25)代谢性酸中毒(pH <7.20),48%(12/25)插管,36%(9/25)使用血管加压药。
  • 40%(10/25)发生凝血障碍(PT > 15s),24%(6/25)接受连续肾脏替代治疗,总死亡率24%。
  • 每年病例数从2015-2019年的1-4例增至2020年的8例,提示使用频率增加。

适用人群与场景

  • 对乙酰氨基酚(APAP)作为主要摄入毒物、接受N-乙酰半胱氨酸(NAC)治疗并接受氟美吡唑治疗的病例(ToxIC数据库2015年1月至2020年7月)。
  • 排除APAP非主要毒物、未用NAC或氟美吡唑明确用于其他适应症者。

研究设计与关键结果

  • 研究类型:ToxIC数据库二次分析,共纳入25例接受氟美吡唑治疗的APAP中毒病例。
  • 每年病例数:2015-2019年间每年1-4例,2020年8例。
  • 25例中17例(68%)为已知急性摄入。
  • 25例中18例(72%)发生肝毒性(AST或ALT > 1000 IU/L)。
  • 25例中10例(40%)发生凝血障碍(PT > 15s)。
  • 25例中18例(72%)发生代谢性酸中毒(pH <7.20)。
  • 25例中12例(48%)接受插管,9例(36%)使用血管加压药,6例(24%)接受连续肾脏替代治疗。
  • 总死亡率为24%。

证据类型、等级与局限

  • 证据类型:基于ToxIC数据库的二次分析(观察性研究)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在一小部分危重且急性APAP中毒的患者中,氟美吡唑的使用频率正在增加。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

INTRODUCTION: Fomepizole inhibits formation of toxic acetaminophen (APAP) metabolites and may prevent or reverse mitochondrial toxicity. Given these mechanisms, it may be beneficial in patients with severe APAP toxicity. Current patterns of use for this indication are not well-studied.

METHODS: This is a secondary analysis of patients enrolled in the Toxicology Investigators Consortium (ToxIC) database from January 2015 to July 2020. We queried cases in which APAP was listed as an ingested agent and fomepizole was also administered. We excluded cases in which APAP was not the primary agent, N-acetylcysteine (NAC) was not administered, or fomepizole was explicitly administered for another indication. Additionally, we sent a survey to each ToxIC site that administered fomepizole for APAP toxicity to better understand when, why, and how they were using it for this indication.

RESULTS: Twenty-five cases of fomepizole administration following an APAP ingestion met our inclusion criteria. There were one to four cases per year between 2015 and 2019 and eight cases in 2020. Seventeen of 25 (68%) cases were for a known acute ingestion. Eighteen of 25 (72%) patients developed hepatotoxicity (AST or ALT > 1000 IU/L) and 10 of 25 (40%) developed coagulopathy (PT > 15s). This was an ill patient population, with 18 of 25 (72%) developing metabolic acidosis (pH <7.20), 12 of 25 (48%) were intubated, 9 of 25 (36%) receiving vasopressors, and 6 of 25 (24%) receiving continuous renal replacement therapy. Overall, mortality was 24%.

CONCLUSION: The use of fomepizole is increasing in frequency in a small subset of critically ill and acutely APAP-poisoned patients.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Filip AB, Berg SE, Mullins ME, et al. Fomepizole as an adjunctive therapy for acetaminophen poisoning: cases reported to the toxicology investigators consortium (ToxIC) database 2015-2020. Clin Toxicol (Phila). 2022. PMID: 35510880. doi:10.1080/15563650.2022.2070071

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。